Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors

(2012) Éva Ágai-Csongor et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Oral Antipsychotic Update: A Brief Review of New and Investigational Agents for the Treatment of Schizophrenia

(2012) Leslie Citrome   CNS SPECTRUMS

Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia

(2012) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHIATRY

In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors

(2011) Yoshihiro Tadori et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacokinetics and metabolism update for some recent antipsychotics

(2011) Silvio Caccia   Expert Opinion on Drug Metabolism & Toxicology

Drug safety evaluation of ziprasidone

(2011) Leslie Citrome   Expert Opinion On Drug Safety

Olanzapine–fluoxetine combination for the treatment of bipolar depression

(2011) Leslie Citrome   EXPERT OPINION ON PHARMACOTHERAPY

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

(2011) István Gyertyán et al.   NEUROCHEMISTRY INTERNATIONAL

Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography

(2011) Nicholas Seneca et al.   PSYCHOPHARMACOLOGY

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties

(2011) Adrian Newman-Tancredi et al.   PSYCHOPHARMACOLOGY

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

(2010) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

(2010) B. Kiss et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials

(2010) Ayşegül Yildiz et al.   NEUROPSYCHOPHARMACOLOGY

Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

(2010) Leslie Citrome   POSTGRADUATE MEDICINE

P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients

(2009) S. Potkin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

(2009) Jan Volavka et al.   EXPERT OPINION ON PHARMACOTHERAPY

P.3.c.051 Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers

(2008) M. Kapás et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents

(2008) Katalin Deák et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Sensitive LC–MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine

(2007) Gabriella Pásztor Mészáros et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS